Literature DB >> 8055014

Cancer cachexia: prevention, early diagnosis, and management.

F D Ottery.   

Abstract

Cachexia is the most common paraneoplastic syndrome of malignancy and is characterized by anorexia, early satiety, severe body compositional change with weight loss, adipose and muscle loss, weakness (asthenia), anemia, and edema. Cause of death in as many as 20% of patients with cancer is associated with tumor-induced and treatment-related malnutrition and inanition. Early diagnosis of cancer malnutrition often is missed because of lack of attention by the oncology team. The importance of understanding the basics of nutritional oncology by the entire healthcare team (physician, nurse, pharmacist, dietitian, social worker, physical and speech therapists) and the patient and family is outlined with practical interventions being specified. An algorithm for an optimal nutritional approach in patients with cancer is included, with emphasis on early diagnosis and intervention for maintenance of nutritional, body compositional, and functional status of the oncology patients. Quality-of-life issues, pharmacologic intervention in cachexia, and necessity of cooperative oncology group involvement in nutritional oncology are discussed.

Entities:  

Mesh:

Year:  1994        PMID: 8055014

Source DB:  PubMed          Journal:  Cancer Pract        ISSN: 1065-4704


  29 in total

Review 1.  Anorexia-Cachexia syndrome in cancer: implications of the ubiquitin-proteasome pathway.

Authors:  Carlos Camps; Vega Iranzo; Roy M Bremnes; Rafael Sirera
Journal:  Support Care Cancer       Date:  2006-07-04       Impact factor: 3.603

2.  Microfluidic approaches for cell-based molecular diagnosis.

Authors:  Dong Jun Lee; John Mai; Tony Jun Huang
Journal:  Biomicrofluidics       Date:  2018-09-14       Impact factor: 2.800

3.  Malnutrition screening programs in adult cancer patients: clinical practice is hungry for evidence.

Authors:  K Biggs
Journal:  Curr Oncol       Date:  2012-10       Impact factor: 3.677

4.  Nutrition support in surgical patients with colorectal cancer.

Authors:  Yang Chen; Bao-Lin Liu; Bin Shang; Ai-Shan Chen; Shi-Qing Liu; Wei Sun; Hong-Zhuan Yin; Jian-Qiao Yin; Qi Su
Journal:  World J Gastroenterol       Date:  2011-04-07       Impact factor: 5.742

5.  Preoperative Nutritional Assessment in Elderly Cancer Patients Undergoing Elective Surgery: MNA or PG-SGA?

Authors:  S P Dubhashi; Akshat Kayal
Journal:  Indian J Surg       Date:  2012-12-07       Impact factor: 0.656

6.  Potential benefits of early nutritional intervention in adults with upper gastrointestinal cancer: a pilot randomised trial.

Authors:  Mary Anne Silvers; June Savva; Catherine E Huggins; Helen Truby; Terry Haines
Journal:  Support Care Cancer       Date:  2014-06-08       Impact factor: 3.603

7.  Nutritional screening tools in daily clinical practice: the focus on cancer.

Authors:  Michèle Leuenberger; Silvia Kurmann; Zeno Stanga
Journal:  Support Care Cancer       Date:  2010-01-20       Impact factor: 3.603

8.  Association of nutritional status and serum albumin levels with development of toxicity in patients with advanced non-small cell lung cancer treated with paclitaxel-cisplatin chemotherapy: a prospective study.

Authors:  Oscar Arrieta; Rosa M Michel Ortega; Geraldine Villanueva-Rodríguez; Maria G Serna-Thomé; Diana Flores-Estrada; Consuelo Diaz-Romero; Cindy M Rodríguez; Luis Martínez; Karla Sánchez-Lara
Journal:  BMC Cancer       Date:  2010-02-21       Impact factor: 4.430

9.  Clinical application of subjective global assessment in Chinese patients with gastrointestinal cancer.

Authors:  Bei-Wen Wu; Tao Yin; Wei-Xin Cao; Zhi-Dong Gu; Xiao-Jin Wang; Min Yan; Bing-Ya Liu
Journal:  World J Gastroenterol       Date:  2009-07-28       Impact factor: 5.742

10.  Subjective taste and smell changes in treatment-naive people with solid tumours.

Authors:  L Spotten; C Corish; C Lorton; P Ui Dhuibhir; N O'Donoghue; B O'Connor; M Cunningham; N El Beltagi; C Gillham; D Walsh
Journal:  Support Care Cancer       Date:  2016-03-05       Impact factor: 3.603

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.